Skip to main content

Advertisement

Table 1 Baseline characteristics of HF outpatients before and after propensity score matching, by SUA quartiles

From: Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure

  Quartiles of SUA in 4684 HF outpatients 1856 HF Outpatients after PSM
1 (n = 1187) 2 (n = 1169) 3 (n = 1154) 4 (n = 1174) P-value SUA
Quartile 1–3
(n = 928)
SUA
Quartile 4
(n = 928)
P-value
Se-uric acid, μmol/L 310.6 ± 51.5 405.4 ± 35.8 490.3 ± 36.5 635.2 ± 88.2 < 0.001 427.7 ± 80.3 633.3 ± 85.3 < 0.001
Se-uric acid, mg/dL 5.22 ± 0.87 6.82 ± 0.60 8.24 ± 0.61 10.68 ± 1.48   7.19 ± 1.35 10.65 ± 1.43  
Male gender, % 73.0 73.7 74.5 71.9 0.527 73.5 73.3 0.916
Age, years 68.0 ± 12.8 68.8 ± 11.9 69.5 ± 12.1 71.9 ± 11.1 < 0.001 71.3 ± 11.3 71.4 ± 11.7 0.770
Body mass index, kg/m2 25.3 ± 4.7 26.2 ± 5.0 27.0 ± 5.3 26.9 ± 5.3 < 0.001 26.5 ± 5.2 26.6 ± 5.1 0.683
Smoking, % 18.5 15.9 13.8 13.0 0.001 14.3 13.8 0.738
Medical history
 Diabetes mellitus, % 15.9 18.7 19.8 24.0 < 0.001 20.8 21.6 0.691
 Ischaemic heart disease, % 55.1 54.5 56.1 58.1 0.334 57.8 57.5 0.919
 Hypertension, % 22.9 32.8 33.7 38.8 < 0.001 36.8 38.7 0.395
 Claudication/stroke, % 13.6 14.8 15.2 17.2 0.106 17.6 17.1 0.806
 PCI/CABG, % 37.2 39.8 37.7 37.7 0.575 38.7 38.6 0.968
 Reduced renal function, % 21.6 31.9 47.4 71.9 < 0.001 67.1 68.5 0.518
Physical findings
 Heart rate, beats/min 71.8 ± 14.3 71.9 ± 14.4 73.0 ± 15.5 73.6 ± 15.5 0.008 74.5 ± 16.1 73.7 ± 15.3 0.265
 SBP, mmHg 127.9 ± 22.2 128.1 ± 22.7 127.0 ± 21.7 123.4 ± 22.5 < 0.001 125.3 ± 22.0 124.4 ± 22.4 0.398
 LVEF, % 33.4 ± 11.1 32.7 ± 11.2 32.4 ± 11.6 32.4 ± 12.5 0.131 32.3 ± 11.7 32.2 ± 12.7 0.956
LVEF groups      0.171    0.557
 LVEF< 40% 72.2 74.6 73.2 74.9   74.3 75.6  
 40% ≤ LVEF< 50% 18.6 16.3 18.1 14.6   16.0 14.1  
 LVEF≥50% 9.2 9.1 8.7 10.6   9.8 10.3  
NYHA Class      < 0.001    0.548
 I + II, % 58.4 52.2 47.8 37.6   39.8 36.9  
 III + IV, % 41.7 47.9 52.3 62.4   60.3 63.0  
Medication
 RAS-blocking agent use, % 89.0 90.8 90.1 87.2 0.027 88.8 88.1 0.663
 ACEi dose/day, % of target dose 48.1 ± 36.4 53.1 ± 37.8 54.9 ± 38.0 52.9 ± 41.8 0.001 51.6 ± 38.3 53.1 ± 42.2 0.486
 ARB use, % 14.2 14.7 16.8 17.4 0.089 16.6 17.0 0.804
 β-blocker dose/day, mg 61.1 ± 58.2 74.2 ± 67.4 72.3 ± 61.8 77.7 ± 66.7 < 0.001 76.8 ± 66.1 75.2 ± 65.6 0.605
 Loop diuretics dose/day, mg 34.4 ± 43.9 47.6 ± 53.6 62.9 ± 48.5 87.5 ± 72.5 < 0.001 72.2 ± 70.5 83.4 ± 70.4 0.001
 Calcium channel blocker use, % 7.4 8.2 8.3 8.4 0.785 8.9 7.3 0.225
 Acetylsalicylic acid use, % 51.3 47.9 45.5 43.4 0.001 44.5 43.4 0.644
 Statin use, % 56.0 56.1 54.3 51.8 0.124 51.9 51.6 0.889
Laboratory values
 eGFR, ml/min/1.73 m2 75.3 ± 20.4 69.2 ± 20.5 62.6 ± 21.0 50.9 ± 20.7 < 0.001 54.1 ± 19.8 52.9 ± 20.8 0.205
 Haemoglobin, g/100 mL 13.79 ± 1.57 14.00 ± 1.65 13.89 ± 1.72 13.70 ± 1.89 < 0.001 13.78 ± 1.78 13.75 ± 1.85 0.700
 Se-potassium, mmol/L 4.38 ± 0.41 4.41 ± 0.43 4.38 ± 0.49 4.41 ± 0.52 0.136 4.43 ± 0.50 4.40 ± 0.50 0.280
 Se-sodium, mmol/L 139.7 ± 3.3 140.0 ± 3.1 140.0 ± 3.2 139.7 ± 3.4 0.024 139.8 ± 3.3 139.7 ± 3.3 0.530
 Se-cholesterol, mmol/L 4.65 ± 1.23 4.71 ± 1.22 4.79 ± 1.31 4.72 ± 1.33 0.097 4.73 ± 1.29 4.75 ± 1.31 0.745
  1. Values are expressed as mean ± SD or percent. ACEi dose/day, percent of daily enalapril equivalent target dose; ARB, angiotensin receptor blocker; β-blocker dose/day, daily metoprolol equivalent dose; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI/CABG, percutaneous coronary intervention and/or coronary artery bypass graft; PSM, propensity score matching; RAS-blocking agent, renin-angiotensin system blocking agent; SBP, systolic blood pressure; SUA, serum uric acid